Investor Relations Home
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.32 (0.81%)
Data as of 08/17/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
08/01/18The Medicines Company Reports Second-Quarter 2018 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 1, 2018-- The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2018. “During the second quarter of 2018, we continued to advance inclisiran’s development programs, including the accumulation of further promising safety data from 3,660 patients in Phase III trials,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. ... 
Printer Friendly Version
07/26/18The Medicines Company to Announce Second-Quarter 2018 Financial Results on August 1
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 26, 2018-- The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, August 1, 2018, at 8:30 a.m. EDT to discuss its second-quarter 2018 financial results and operational developments. The conference call may be accessed by telephone as follows: U.S./Canada: (877) 359-9508 International: (224) 357-2393 Conference ID: 5847059 A taped replay of th... 
Printer Friendly Version
06/27/18The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following [Third] Review of Unblinded Data
–More than 1,550 patient-years of safety data accumulated to date – a three-fold increase over total patient exposure through Phase II trials– –At the time of IDMC review, [substantially] all patients in Phase III trials had received two doses of inclisiran or placebo– –Phase III trials of inclisiran progressing as planned with no material safety observations to date– PARSIPPANY, N.J.--(BUSINESS WIRE)--Jun. 27, 2018-- The Medic... 
Printer Friendly Version
06/26/18New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jun. 26, 2018-- The Medicines Company (NASDAQ: MDCO) today announced the presentation of new data from a pre-specified, sub-group analysis of dosing, efficacy and safety of inclisiran in patients with diabetes from the ORION-1 Phase II trial at the American Diabetes Association (ADA) 78th Scientific Sessions® in Orlando (ADA 2018). Professor Lawrence Leiter, Director of the Lipid Clinic, Associate Directo... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.